Administration of IL‐6 and oncostatin M has been shown to suppress breast cancer growth in vitro (Chiu et al., 1996; Hojman et al., 2011), suggesting that IL‐6 and other myokines could have a direct role in reducing cancer progression by modulating key signaling pathways involved in cancer cell proliferation. This evidence concerns the gene IL6 and breast cancer.